Cellectar Biosciences Inc

Cellectar Biosciences reported second-quarter 2026 results, highlighting increased R&D investment and a stronger balance sheet compared to the prior year. Cash and cash equivalents stood at $34.0 million as of June 30, 2026, which the company said is adequate to fund operations into the second quarter of 2027. R&D expenses rose to $4.6 million from $2.4 million in Q2 2025, driven by initiation of the Waldenström macroglobulinemia confirmatory study and the CLR 125 trial in triple negative breast cancer, while G&A expenses decreased to $2.6 million from $3.6 million. Net loss attributable to common stockholders was $6.9 million, or $0.57 per share, compared to $5.4 million, or $3.39 per share, in Q2 2025. The company is preparing for a Phase 3 confirmatory study of Iopofosine I 131, with site activation initiated and first patient dosing expected in early 2027, and plans to submit an NDA in mid-2027 under the FDA's Accelerated Approval Program.

Cellectar Biosciences announced the publication of results from a Phase 1 dose-escalation study of iopofosine I 131 in heavily pretreated relapsed/refractory multiple myeloma patients in the peer-reviewed journal Cancers. The study enrolled 31 patients who had received a median of four prior lines of therapy and evaluated both single-dose and fractionated-dose regimens of iopofosine I 131 in combination with low-dose dexamethasone. Among 26 efficacy-evaluable patients, 84.6% achieved stable disease or better, and a 30% overall response rate was observed in the subgroup of 10 patients receiving at least 60 mCi of iopofosine I 131, while the overall response rate across all evaluable patients was 15.4% with four partial responses. The safety profile was favorable and manageable, with adverse events primarily consisting of predictable and reversible hematologic toxicities and no new safety signals identified. The authors recommended a fractionated Phase 2 regimen of 15 mCi/m² administered on days 1 and 7 with weekly low-dose dexamethasone.